As of Sep 30
| +0.21 / +2.62%|
The 7 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 10.00. The median estimate represents a +33.82% increase from the last price of 8.22.
The current consensus among 8 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.